HC Wainwright Weighs in on Geron's Q1 Earnings (NASDAQ:GERN)

Geron Co. (NASDAQ:GERN - Free Report) - Equities researchers at HC Wainwright issued their Q1 2025 earnings estimates for shares of Geron in a research note issued to investors on Thursday, November 7th. HC Wainwright analyst E. Bodnar anticipates that the biopharmaceutical company will post earnings of ($0.03) per share for the quarter. HC Wainwright currently has a "Buy" rating and a $8.00 price objective on the stock. The consensus estimate for Geron's current full-year earnings is ($0.34) per share. HC Wainwright also issued estimates for Geron's Q2 2025 earnings at ($0.03) EPS and Q3 2025 earnings at ($0.02) EPS.

GERN has been the topic of a number of other research reports. Scotiabank started coverage on shares of Geron in a research report on Wednesday, October 16th. They set a "sector outperform" rating and a $6.00 target price on the stock. Wedbush reissued an "outperform" rating and issued a $8.00 price target on shares of Geron in a research note on Thursday, August 8th. Leerink Partners started coverage on shares of Geron in a research note on Monday, September 9th. They set an "outperform" rating and a $7.00 price objective for the company. Needham & Company LLC restated a "buy" rating and issued a $6.00 target price on shares of Geron in a report on Friday, August 9th. Finally, Leerink Partnrs raised shares of Geron to a "strong-buy" rating in a research note on Monday, September 9th. One investment analyst has rated the stock with a sell rating, one has given a hold rating, nine have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $7.05.

Geron Stock Down 2.8 %

NASDAQ:GERN traded down $0.12 on Monday, reaching $4.13. The stock had a trading volume of 3,534,627 shares, compared to its average volume of 10,430,890. Geron has a 12-month low of $1.64 and a 12-month high of $5.34. The firm's fifty day moving average is $4.31 and its two-hundred day moving average is $4.32. The company has a debt-to-equity ratio of 0.12, a current ratio of 3.61 and a quick ratio of 3.60.

Geron (NASDAQ:GERN - Get Free Report) last released its quarterly earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.04) EPS for the quarter, beating the consensus estimate of ($0.09) by $0.05. Geron had a negative net margin of 682.48% and a negative return on equity of 67.10%. The business had revenue of $28.27 million for the quarter, compared to analyst estimates of $18.97 million. During the same period in the prior year, the business earned ($0.08) earnings per share. The company's quarterly revenue was up 17138.4% on a year-over-year basis.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. National Bank of Canada FI increased its stake in shares of Geron by 1,200.0% during the second quarter. National Bank of Canada FI now owns 6,500 shares of the biopharmaceutical company's stock valued at $28,000 after acquiring an additional 6,000 shares during the period. Crewe Advisors LLC boosted its position in Geron by 870.0% during the first quarter. Crewe Advisors LLC now owns 9,700 shares of the biopharmaceutical company's stock worth $32,000 after purchasing an additional 8,700 shares during the period. Kingsview Wealth Management LLC acquired a new position in Geron in the 1st quarter valued at $34,000. American Trust bought a new position in shares of Geron in the first quarter worth about $38,000. Finally, Rovin Capital UT ADV bought a new position in Geron in the 3rd quarter worth approximately $62,000. 73.71% of the stock is currently owned by institutional investors.

Geron Company Profile

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.